RCSB PDB - 1UYM: Human Hsp90-beta with PU3 (9-Butyl-8(3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine) (original) (raw)
Structure-Activity Relationships in Purine-Based Inhibitor Binding to Hsp90 Isoforms
[Wright, L.](/search?q=citation.rcsb%5Fauthors:Wright, L.), [Barril, X.](/search?q=citation.rcsb%5Fauthors:Barril, X.), [Dymock, B.](/search?q=citation.rcsb%5Fauthors:Dymock, B.), [Sheridan, L.](/search?q=citation.rcsb%5Fauthors:Sheridan, L.), [Surgenor, A.](/search?q=citation.rcsb%5Fauthors:Surgenor, A.), [Beswick, M.](/search?q=citation.rcsb%5Fauthors:Beswick, M.), [Drysdale, M.](/search?q=citation.rcsb%5Fauthors:Drysdale, M.), [Collier, A.](/search?q=citation.rcsb%5Fauthors:Collier, A.), [Massey, A.](/search?q=citation.rcsb%5Fauthors:Massey, A.), [Davies, N.](/search?q=citation.rcsb%5Fauthors:Davies, N.), [Fink, A.](/search?q=citation.rcsb%5Fauthors:Fink, A.), [Fromont, C.](/search?q=citation.rcsb%5Fauthors:Fromont, C.), [Aherne, W.](/search?q=citation.rcsb%5Fauthors:Aherne, W.), [Boxall, K.](/search?q=citation.rcsb%5Fauthors:Boxall, K.), [Sharp, S.](/search?q=citation.rcsb%5Fauthors:Sharp, S.), [Workman, P.](/search?q=citation.rcsb%5Fauthors:Workman, P.), [Hubbard, R.E.](/search?q=citation.rcsb%5Fauthors:Hubbard, R.E.)
(2004) Chem Biol 11: 775
PubMed: 15217611 Search on PubMed
PubMed Abstract:
Inhibition of the ATPase activity of the chaperone protein HSP90 is a potential strategy for treatment of cancers. We have determined structures of the HSP90alpha N-terminal domain complexed with the purine-based inhibitor, PU3, and analogs with enhanced potency both in enzyme and cell-based assays. The compounds induce upregulation of HSP70 and downregulation of the known HSP90 client proteins Raf-1, CDK4, and ErbB2, confirming that the molecules inhibit cell growth by a mechanism dependent on HSP90 inhibition. We have also determined the first structure of the N-terminal domain of HSP90beta, complexed with PU3. The structures allow a detailed rationale to be developed for the observed affinity of the PU3 class of compounds for HSP90 and also provide a structural framework for design of compounds with improved binding affinity and drug-like properties.
Organizational Affiliation:
Vernalis (R&D) Ltd., Granta Park, Abington, Cambridge CB1 6GB, UK.